Wells Fargo analyst Tiago Fauth raised the firm’s price target on Liquidia to $51 from $44 and keeps an Overweight rating on the shares. The firm believes the pulmonary hypertension market is poised to change. With key opinion leader feedback from a Respimat developer, and counter to current market sentiment, Wells sees Liquidia’s (LQDA) L606 as competitive with Insmed’s (INSM) TPIP.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on LQDA:
- Liquidia Technologies put volume heavy and directionally bearish
- Liquidia price target raised to $19 from $16 at Oppenheimer
- Liquidia rises 7.7%
- Liquidia price target raised to $55 from $50 at H.C. Wainwright
- Liquidia: Exceptional Yutrepia Launch, Advancing PH Pipeline, and Strengthening Financial Profile Support Buy Rating